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ABSTRACT
CONTEXT AND OBJECTIVE: C-reactive protein (CRP) is commonly used as a marker for inflammatory states and for early identification of infection. This 
study aimed to investigate CRP as a marker for infection in patients with postoperative septic shock. 
DESIGN AND SETTING: Prospective, single-center study, developed in a surgical intensive care unit at Hospital das Clínicas, Faculdade de Medicina da 
Universidade de São Paulo. 
METHODS: This study evaluated 54 patients in the postoperative period, of whom 29 had septic shock (SS group) and 25 had systemic inflammatory 
response syndrome (SIRS group). All of the patients were monitored over a seven-day period using the Sequential Organ Failure Assessment (SOFA) score 
and daily CRP and lactate measurements. 
RESULTS: The daily CRP measurements did not differ between the groups. There was no correlation between CRP and lactate levels and the SOFA score in the 
groups. We observed that the plasma CRP concentrations were high in almost all of the patients. The patients presented an inflammatory state postoperatively 
in response to surgical aggression. This could explain the elevated CRP measurements, regardless of whether the patient was infected or not. 
CONCLUSIONS: This study did not show any correlation between CRP and infection among patients with SIRS and septic shock during the early 
postoperative period. 
RESUMO
CONTEXTO E OBJETIVO: A proteína C reativa (PCR) é muito usada como marcador de estados inflamatórios e na identificação precoce de infecção. Este 
estudo teve como proposta investigar a PCR como marcadora de infecção em pacientes em choque séptico no período pós-operatório. 
TIPO DE ESTUDO E LOCAL: Estudo prospectivo, monocêntrico, desenvolvido numa unidade de terapia intensiva pós-operatória do Hospital das Clínicas 
da Faculdade de Medicina da Universidade de São Paulo. 
MÉTODOS: Foram avaliados 54 pacientes no pós-operatório, sendo 29 deles com choque séptico (grupo SS) e 25 com síndrome da resposta inflamatória 
sistêmica (grupo SI). Todos os pacientes foram acompanhados durante sete dias pelo escore SOFA (Sequential Organ Failure Assessment) e com 
dosagens diárias de PCR e lactato.
RESULTADOS: As dosagens de PCR não diferiram entre os grupos. Não foi observada correlação entre dosagem de PCR e lactato ou escore SOFA nos 
grupos estudados. Observamos que as concentrações plasmáticas de PCR estavam elevadas em quase todos os pacientes avaliados. Os pacientes 
no pós-operatório apresentam estado inflamatório em resposta à agressão cirúrgica, sendo este fato capaz de explicar as dosagens de PCR elevadas, 
independentemente de o paciente estar ou não infectado.
CONCLUSÕES: Este estudo não evidenciou correlação entre PCR e infecção nos pacientes com síndrome da resposta inflamatória sistêmica e choque 
séptico no período pós-operatório precoce.
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INTRODUCTION
Systemic inflammatory response syndrome (SIRS) is a common 
event among critically ill patients. Whether accompanied by infection 
or not, it is frequent postoperatively, particularly in relation to trauma, 
burns, pancreatitis or pulmonary diseases.1 Conversely, severe sepsis and 
septic shock are states of systemic inflammation in response to infec-
tious agents that may lead to multiple organ system failure, and these 
are a frequent cause of postoperative mortality in intensive care units 
(ICUs).2 
The release of inflammatory response mediators over the course of 
such diseases gives physicians a useful tool for marking the severity of 
sepsis.3 One of these markers, C-reactive protein (CRP), is produced by 
the liver in response to tissue injury or infection. It reaches its maximum 
serum concentration around 24 hours after the inflammatory process 
sets in and slowly decreases thereafter.4 Previous studies have presented 
doubtful conclusions regarding the efficiency of CRP for differentiat-
ing infection from inflammation, especially during the postoperative 
period.5,6
OBJECTIVE
Considering the importance of distinguishing inflammatory septic 
response from non-infective events, this study had the aim of evaluating 
the role of CRP as a marker for infection in critically ill patients during 
the postoperative period.
METHODS
This prospective study was performed in the surgical ICU at Hospi-
tal das Clínicas (HC), Faculdade de Medicina de São Paulo (FMUSP). 
After approval by the local ethics committee, patients admitted to the 
ICU with a diagnosis of SIRS or septic shock (SS) in accordance with 
the definitions of the American College of Chest Physicians/Society 
of Critical Care Medicine Consensus Conference were included.7 In-
formed consent was obtained from the patients or from their next of 
kin.8 Patients under 18 years of age were excluded. 
At the time when patients were admitted into the study, their se-
verity of illness was assessed according to the Acute Physiology And 
Chronic Health Evaluation II score (APACHE II).9 They were also as-
sessed daily by using the Sequential Organ Failure Assessment score 
(SOFA) for seven consecutive days or until their discharge from the 
ICU, if this occurred earlier.10,11 C-reactive protein was measured on 
a daily basis.
For infection to be diagnosed, clinical signs of SIRS and a defined 
source of microbiologically confirmed infection (surgical finding) or 
positive blood, urine, catheter tip or tracheal secretion cultures had to 
be present.5
The patients received conventional therapy regarding antibiotic reg-
imens, serial blood cultures and discharge criteria. The relevant clinical 
and laboratory tests were conducted daily throughout the study.
Blood samples for CRP measurements were thawed and assayed 
in batches in an automated analyzer (Behring Nephelometer Analyzer 
II, Dade Behring, Marburg, Denmark) for particle-enhanced immu-
nonephelometry using commercial kits. The analytical sensitivity and 
accuracy of the CRP assays was 0.0175 mg/l (coefficient of variation, 
CV = 7.6%).
Statistical analysis to evaluate changes in variables over the course 
of the ICU stay was performed by means of two-way analysis of vari-
ance (ANOVA). Student’s t-test was used to analyze differences between 
groups. P < 0.05 was considered significant. The sample size was calcu-
lated as 25 patients per group, based on the standard normal deviation 
for α = 0.05 and β = 0.20.12 
RESULTS
Out of the 59 patients enrolled, 29 formed the SS group and 25 
formed the SIRS group. Five patients were excluded after their next of 
kin withdrew their signed consent. The patients’ characteristics at the 
time of admission to the study, their prior or preexisting conditions, 
the type of surgery and the outcome data are presented in Table 1. 
The microbiological characteristics of both groups are presented in 
Table 2. The evolution of SOFA scores in the two groups is presented 
in Figure 1. The daily evolution of CRP in the two groups is presented in 
Figure 2. Serum lactate was different between groups, as shown 
in Figure 3.
There was no correlation between CRP and SOFA in either group 
(r = 0.004; P = 0.99). There was a positive correlation between CRP 
and lactate in both groups, but without statistical significance (r = 0.60; 
P = 0.15).
The daily evolution of CRP plasma concentrations among patients 
who died and survivors is presented in Figure 4. The mortality rate over 
seven days was 38% for the SS group (11 out of 29 patients) and 24% 
for the SIRS group (six out of 25 patients) (P = 0.28). Over 28 days, the 
Table 1. Patient characteristics in the two groups, at the time of admission 
to the study 
Group SS SIRS P
Characteristics n = 29 n = 25
Age (years) 59.4 ± 16.4 57.2 ± 19.1 NS
Male sex 55% 56% NS
Weight (kg) 67.5 ± 13 67.3 ± 10.8 NS
APACHE II score 19 ± 5 16 ± 5 0.02
SOFA score 8.4 ± 3.7 8.1 ± 4.4 0.01
Preexisting conditions n (%) n (%)
Hypertension 10 (34) 7 (28) NS
Myocardial infarction 5 (17) 3 (12) NS
Diabetes 4 (14) 4 (16) NS
Liver disease 3 (10) 1 (4) NS
COPD 2 (7) 2 (8) NS
Cancer 6 (21) 5 (20) NS
Surgery
Multiple trauma (excluding head trauma) 1 (3.4) 1 (4) NS
Gastrointestinal surgery 21 (72) 15 (60) NS
Abdominal aneurysm repair 2 (7) 2 (8) NS
Thoracic surgery 1 (3.4) 1 (4) NS
Urologic surgery 3 (10) 2 (8) NS
Other indicators of severity (days) Mean ± SD Mean ± SD
Mechanical ventilation 4.4 ± 2.6 3.2 ± 2.3 NS
Shock (use of vasopressor) 3.7 ± 2.4 2.3 ± 2.2 0.03
SS = group with septic shock; SIRS = group with systemic inflammatory response syndrome; APACHE = acute 
physiology and chronic health evaluation; SOFA = sequential organ failure assessment; COPD = chronic 
obstructive pulmonary disease; NS = not statistically significant; SD = standard deviation.
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Table 2. Microbiological analysis on patients in the two groups, including surgical procedure performed, antibiotic therapy, etiological infectious agent and 
source from which the agent was isolated
Patient Surgery/pathological condition Antibiotics Type of organism Type of culture
1-SS Cholecystectomy/biliary abscess Vancomycin + cefepime S. aureus Abscess culture
2-SS Empyema pleural drainage Ceftriaxone + clindamycin S. pyogenes Pleural abscess culture
3-SS Cholecystectomy/biliary abscess Ceftriaxone + metronidazole - Negative cultures
4-SS Cystectomy/pyuria Ceftriaxone + metronidazole - Negative cultures
5-SS Abdominal aneurysm repair Ceftazidime + clindamycin P. aeruginosa Blood culture
6-SS Colectomy/cavity contamination Ceftriaxone + metronidazole - Negative cultures
7-SS Calcaneal exposure fracture Ciprofloxacin E. faecalis Surgical site culture
8-SS Pyonephrosis drainage Ceftriaxone K. pneumoniae Urinary culture
9-SS Sigmoidectomy Ceftriaxone + metronidazole A. baumanii Blood culture
10-SS Hemicolectomy Ceftriaxone + metronidazole Candida albicans Blood culture
11-SS Enterectomy/mesenteric ischemia Ceftriaxone + metronidazole - Negative cultures
12-SS Pancreatic-duodenal resection Ceftriaxone Serratia marcesens BAL
13-SS Pancreatic-duodenal resection Ceftriaxone + metronidazole S. coag negative Blood culture
14-SS Retroperitoneal abscess drainage Cefepime + vancomycin + imipenem P. aeruginosa Blood culture
15-SS Abdominal aneurysm repair Vancomycin + imipenem S. aureus Blood culture
16-SS Sigmoidectomy/perforative lesion Ceftriaxone + metronidazole Serratia marcesens Ascites culture
17-SS Colectomy Cefepime + vancomycin S. aureus Blood culture
18-SS Gastric ulcer Ceftriaxone + metronidazole - Negative cultures
19-SS Cholecystectomy Ciprofloxacin + metronidazole Escherichia coli Urinary culture
20-SS Hemicolectomy Cefepime + vancomycin + metronidazole E. cloacae Blood culture
21-SS Enterectomy/cavity contamination Vancomycin + imipenem - Negative cultures
22-SS Colectomy Ceftriaxone + metronidazole A. baumanii Blood culture
23-SS Colectomy Ceftriaxone + metronidazole P. aeruginosa Blood culture
24-SS Enterectomy/cavity contamination Ceftriaxone + metronidazole - Negative cultures
25-SS Cervical abscess drainage Imipenem + vancomycin + metronidazole K. pneumoniae Blood culture
26-SS Sigmoidectomy/perforative lesion Ceftriaxone + metronidazole P. aeruginosa Blood culture
27-SS Sigmoidectomy Cefepime + metronidazole S. aureus Blood culture
28-SS Pyonephrosis drainage Cefepime + metronidazole - Negative cultures
29-SS Colectomy Ceftriaxone + metronidazole P. aeruginosa BAL
1-SIRS Pancreatic-duodenal resection Cephalothin _ Blood culture
2-SIRS Aortic-iliac bypass Clindamycin _ Blood culture
3-SIRS Hemicolectomy Cefoxitin _ _
4-SIRS Nephrectomy Cephalotin _ Blood and urinary
5-SIRS Gastric resection Cefoxitin _ Blood culture
6-SIRS Femoral exposure fracture Clindamycin + gentamicin _ Surgical site culture
7-SIRS Abdominal aneurysm repair Cephalothin _ Blood and urinary
8-SIRS Appendectomy Cephalothin _ Blood culture
9-SIRS Hemicolectomy Cefoxitin _ Blood and urinary
10-SIRS Prostatectomy Cefazolin _ Blood culture
11-SIRS Colectomy Cefoxitin _ _
12-SIRS Iliac endarterectomy Cefazolin _ Blood and urinary
13-SIRS Colectomy Cefoxitin _ Blood culture
14-SIRS Cholecystectomy Cefazolin _ _
15-SIRS Colectomy Cefoxitin _ Blood culture
16-SIRS Cholecystectomy Cephalothin _ _
17-SIRS Hemicolectomy Cefoxitin _ Blood and urinary
18-SIRS Lobectomy Cefazolin _ Blood culture
19-SIRS Sigmoidectomy Ceftriaxone + metronidazole _ Blood culture
20-SIRS Ulnar exposure fracture Clindamycin + gentamicin _ Surgical site culture
21-SIRS Femoral exposure fracture Clindamycin + gentamicin _ Surgical site culture
22-SIRS Splenectomy Cefazolin _ _
23-SIRS Abdominal aneurysm repair Cefazolin _ Blood and urinary
24-SIRS Enterectomy Cefoxitin _ Blood culture
25-SIRS Cholecystectomy Cefazolin _ Blood culture
SS = group with septic shock; SIRS = group with systemic inflammatory response syndrome; S. aureus = Staphylococcus aureus, S. pyogenes = Streptococcus pyogenes, P. aeruginosa = Pseudomonas aeruginosa, E. faecalis = 
Enterobacter faecalis, K. pneumoniae = Klebsiella pneumoniae, A. baumanii = Acinetobacter baumanii, S. coag negative = Staphylococcus coagulase negative; E. cloacae = Enterobacter cloacae; BAL = bronchoalveolar lavage.
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Figure 1. Daily evolution of sequential organ failure assessment (SOFA) 
score among the SS (septic shock) and SIRS (systemic inflammatory 
response syndrome) groups. 
*Statistically significant (P < 0.05). 
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Figure 2. Mean C-reactive protein (CRP) measurements in the two groups. 
SS = group with septic shock; SIRS = group with systemic inflammatory response syndrome; 
differences were not statistically significant in any of the comparisons.
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SS = group with septic shock; SIRS = group with systemic inflammatory response syndrome. 
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Figure 3. Mean serum lactate measurements in the two groups
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Figure 4. Outcome prognosis according to C-reactive protein (CRP) levels. 
der septic shock.10 It considered that CRP was a good marker for organ 
dysfunction after septic shock had been diagnosed. However, disagree-
ing with that report, the results presented here, as well as in previously 
published results,19,20 did not establish any positive correlation between 
CRP and SOFA.
mortality rates in the SS and SIRS groups were, respectively, 62% (18 
out of 29) and 44% (11 out of 25) (P = 0.17). The SS group presented 
a seven-day relative risk (RR) of mortality of 1.6 (95% confidence in-
terval, CI: 0.99-2.59), in comparison with the SIRS group; the 28-day 
relative risk of mortality was 1.4 (95% CI: 0.83-2.35).
DISCUSSION
The present study did not show any correlation between CRP and 
diagnoses of infection among postoperative patients with SIRS and sep-
tic shock. Nor did the SOFA score correlate with CRP measurements.
The patterns of cytokine production differ for different inflamma-
tory conditions, as does the acute-phase response. Acute-phase changes 
reflect the presence and intensity of inflammation. Therefore, they have 
been used as a clinical guide for diagnosis and care. Conversely, serum 
CRP has been widely used as a marker for inflammation and tissue in-
jury, as well as for diagnostic purposes, thereby differentiating inflam-
matory and infectious diseases.13 Previous reports have taken the view 
that elevated CRP levels are also associated with adverse outcomes in 
healthy individuals, as well as in patients with stable angina or acute 
coronary syndromes.14
Among patients with plasma CRP concentrations higher than 
10 mg/dl, 80 to 85% have bacterial infections, according to previous 
studies.15,16 In this present study, patients from both groups presented 
plasma CRP concentrations higher than 10 mg/dl during the seven-day 
observation period, but no difference between septic shock (infected) 
and SIRS (non-infected) patients was found, thus contrasting with the 
results of Gabay et al.16 It is important to stress that Meisner et al. ob-
served that CRP plasma concentrations were postoperatively elevated 
in almost all patients, regardless of the type of surgery.6 Suprin et al. 
observed that CRP was not a valuable indicator of infection in a medi-
cal ICU, due to its poor sensitivity and specificity.15 Ugarte et al. re-
ported that CRP levels were not much higher in infected patients with 
shock,17 and this was confirmed by the findings presented here. All the 
patients studied were in the postoperative period. This fact, also accord-
ing to Meisner, could in itself explain the elevated CRP measurements 
observed, regardless of whether infection was present or not. Hence, 
CRP cannot be used as a marker for infection in the early postopera-
tive period.
Higher CRP levels were observed among the patients in the SIRS 
group than among those in the SS group. This can be explained by 
the antibiotic regimens among the septic shock patients. Many patients 
with SIRS received only prophylactic antibiotic therapy, while septic 
shock patients received antibiotics during their entire ICU stay. Given 
that Ventetuolo et al. reported that CRP might be used to follow the re-
sponse to antibiotic therapy,18 the septic patients’ response to the antibi-
otic regimen could be the reason for their lower CRP levels.
The difference in CRP concentrations between patients who sur-
vived and those who did not agrees with previous reports in which this 
protein was considered to be a valuable prognostic marker for death 
among patients with septic shock.5,10
A previous report associated CRP levels and organ failure among 
critically ill patients, although these patients were not specifically un-
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The present study had some limitations. The diagnosis of infection 
was based on the presence of positive cultures from blood, urine, catheter 
or tracheal secretion, or on the presence of a presumed focus of infection 
in the surgical site. It is known that false-negative cultures are a frequent 
finding among critically ill patients. Thus, some septic patients may be 
misdiagnosed as presenting SIRS, instead of sepsis. In order to minimize 
this source of error, patients diagnosed with SIRS who presented any posi-
tive culture during the seven-day observation period were excluded.
CONCLUSION
CRP is not a good predictor for infection among patients present-
ing septic shock during the early postoperative period.
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